The main limitations of the current study are: (I) The levels of IgM and IgG antibodies in the different conditions of COVID-19 (asymptomatic infection, mild, common, severe, and critically severe) need to be evaluated in long-term follow-up study in order to be able to claim effects. The gene discussed is CD40LG; the disease is COVID-19.